Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD3/CD19 Haploidentical HCT in Acute Leukemia
NCT00961142Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2009
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD3/CD19 depleted hematopoietic stem cells in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by University Hospital Tübingen. Started Jun 2009; status: terminated.
02
Drugs
CD3/CD19 depleted hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00961142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961142.